Targeting HIV reservoirs to reduce inflammation in patients
Understanding and targeting the HIV-expressing reservoir to reduce immune activation
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11052612
This study is looking at how HIV can still impact the immune system in people who are taking medication to manage the virus, and it aims to find out what parts of the virus might be causing ongoing inflammation and health problems, so we can improve care for those living with HIV.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11052612 on ClinicalTrials.gov |
What this research studies
This research investigates how HIV continues to affect the immune system even in patients receiving antiretroviral therapy (ART). It aims to identify the specific viral products that contribute to ongoing inflammation and immune activation in people living with HIV. By analyzing blood and gut samples from patients on ART, the study will explore the relationship between low-level HIV expression and inflammation. The goal is to better understand the mechanisms behind persistent health issues in these patients and to develop targeted interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and have achieved viral suppression.
Not a fit: Patients who are not living with HIV or those who are not on antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments that reduce inflammation and enhance the overall health of people living with HIV.
How similar studies have performed: Previous research has shown promise in targeting HIV reservoirs and understanding immune activation, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YUKL, STEVEN A — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: YUKL, STEVEN A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus